tiprankstipranks
Trending News
More News >
Advertisement

RSPH - AI Analysis

Compare

Top Page

RSPH

Invesco S&P 500 Equal Weight Health Care ETF (RSPH)

Rating:71Outperform
Price Target:
$34.00
The overall rating of the Invesco S&P 500 Equal Weight Health Care ETF (RSPH) suggests it is a solid investment option with a balanced mix of strengths and challenges. Holdings like IQVIA and Agilent contribute positively to the fund's rating due to their strong financial performance, strategic growth initiatives, and bullish outlooks. However, weaker holdings such as Moderna and Charles River Laboratories, which face profitability challenges and valuation concerns, may have slightly held back the fund's overall score. Investors should note that the ETF's concentration in the healthcare sector could pose risks tied to industry-specific challenges or regulatory changes.
Positive Factors
Steady Recent Performance
The ETF has shown positive returns over the past month and three months, indicating solid short-term momentum.
Equal Weighting Strategy
The fund's equal weighting approach reduces reliance on a few large companies, promoting balanced exposure across holdings.
Reasonable Expense Ratio
With a 0.4% expense ratio, the ETF offers relatively low costs compared to actively managed funds.
Negative Factors
Sector Concentration Risk
The ETF is heavily focused on the health care sector, making it vulnerable to industry-specific downturns.
Weak Performance of Key Holdings
Several top holdings, including Moderna and Centene, have underperformed year-to-date, dragging on overall returns.
Limited Geographic Diversification
The ETF is almost entirely invested in U.S. companies, offering little exposure to international markets.

RSPH vs. SPDR S&P 500 ETF (SPY)

RSPH Summary

The Invesco S&P 500 Equal Weight Health Care ETF (RSPH) is a fund that focuses on the health care sector, including companies in pharmaceuticals, biotechnology, medical devices, and health care services. Unlike traditional funds, it gives equal weight to each company, ensuring a balanced approach and reducing reliance on larger firms. Some of its holdings include well-known companies like Moderna and Thermo Fisher. Investors might consider this ETF to benefit from the growth and innovation in health care, a sector driven by advancements and aging populations. However, since it focuses solely on health care, its performance is heavily tied to the ups and downs of that industry.
How much will it cost me?The Invesco S&P 500 Equal Weight Health Care ETF (RSPH) has an expense ratio of 0.40%, which means you’ll pay $4 per year for every $1,000 invested. This is slightly higher than average for ETFs because it uses an equal-weight strategy, which requires more active management compared to passively managed funds that track a standard index.
What would affect this ETF?The Invesco S&P 500 Equal Weight Health Care ETF (RSPH) could benefit from advancements in medical technology, increased demand for health care services due to aging populations, and innovation in biotechnology and pharmaceuticals. However, it may face challenges from regulatory changes, pricing pressures in the health care industry, and potential economic downturns that could reduce consumer spending on health care. Its U.S. focus and equal-weight strategy provide diversification but may limit exposure to faster-growing international markets.

RSPH Top 10 Holdings

The Invesco S&P 500 Equal Weight Health Care ETF (RSPH) is a deep dive into the health care sector, with a balanced approach that avoids over-reliance on any single company. Recent performance has been a mixed bag, with IQVIA Holdings and Agilent showing steady growth, buoyed by strong financials and strategic initiatives. Thermo Fisher has also been a bright spot, benefiting from robust operational execution. However, Moderna and Centene have struggled, with profitability challenges and sector-specific headwinds dragging on the fund’s overall performance. With its U.S.-focused portfolio, RSPH offers a diversified yet concentrated bet on health care innovation.
Name
Company Name
Weight %
Market Value
Market Cap
Yearly Gain
Overall Rating
Bio-Techne1.93%$13.94M$9.66B-18.42%
72
Outperform
Universal Health1.93%$13.87M$14.33B8.58%
78
Outperform
Intuitive Surgical1.90%$13.70M$190.57B4.64%
78
Outperform
Centene1.90%$13.68M$18.34B-39.56%
61
Neutral
HCA Healthcare1.89%$13.61M$109.60B29.78%
77
Outperform
IQVIA Holdings1.88%$13.57M$37.10B0.83%
77
Outperform
Regeneron1.87%$13.47M$68.61B-29.25%
79
Outperform
Charles River Labs1.87%$13.47M$8.87B-0.68%
60
Neutral
Waters1.86%$13.44M$20.44B5.17%
72
Outperform
Thermo Fisher1.86%$13.42M$210.82B1.40%
73
Outperform

RSPH Technical Analysis

Technical Analysis Sentiment
Positive
Last Price
Price Trends
50DMA
29.65
Positive
100DMA
29.19
Positive
200DMA
29.23
Positive
Market Momentum
MACD
0.30
Positive
RSI
54.01
Neutral
STOCH
46.01
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For RSPH, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 30.30, equal to the 50-day MA of 29.65, and equal to the 200-day MA of 29.23, indicating a neutral trend. The MACD of 0.30 indicates Positive momentum. The RSI at 54.01 is Neutral, neither overbought nor oversold. The STOCH value of 46.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RSPH.

RSPH Peer Comparison

Comparison Results
Name
Price
Price Target
AUM
Expense Ratio
Overall Rating
$727.51M0.40%
71
Outperform
$927.42M0.62%
71
Outperform
$815.25M0.38%
72
Outperform
$213.47M0.50%
64
Neutral
$143.12M0.29%
66
Neutral
$109.90M0.60%
62
Neutral
Performance Comparison
Ticker
Company Name
Price
Change
% Change
RSPH
Invesco S&P 500 Equal Weight Health Care ETF
30.29
0.12
0.40%
FXH
First Trust Health Care AlphaDEX Fund
IHF
iShares U.S. Healthcare Providers ETF
PINK
Simplify Health Care ETF
PSCH
Invesco S&P SmallCap Health Care ETF
PTH
Invesco DWA Healthcare Momentum ETF
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents
Advertisement